Key facts
- Peptilogics’s last known valuation is $150.0M (May 2025).
- It has raised $194.8M across 4 recorded rounds; the latest was Early Stage VC ($35.8M) in Dec 2020.
- Notable investors include Gaingels, Founders Fund, Innovation Works, Alpha Wave Global, Peter Thiel — 30 tracked in total.
- Peptilogics has filed 4 Form Ds with the SEC since 2016, most recently Dec 2020 ($35.8M sold to 19 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 30 names
- ·Watchlist + deal alerts for Peptilogics
Funding rounds
4 roundsAbout Peptilogics
Developer of a therapeutic and drug discovery peptide platform designed to treat multidrug-resistant bacterial infections. The company's platform offers a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) that has preclinical effectiveness against resistant bacteria and biofilms, enabling doctors to identify and treat bacterial infections at an affordable cost.
- Sector
- Healthcare
- HQ
- Pittsburgh, PA, United States
- Founded
- 2013
- Employees
- 21
- Website
- peptilogics.com/
- Ownership
- Privately Held (backing)
Peptilogics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Peptilogics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Peptilogics in its N-PORT filings yet. We sweep new filings monthly.